Literature DB >> 19616449

The immunobiology of CD154-CD40-TRAF interactions in atherosclerosis.

David Engel1, Tom Seijkens, Marjorie Poggi, Maryam Sanati, Larissa Thevissen, Linda Beckers, Erwin Wijnands, Dirk Lievens, Esther Lutgens.   

Abstract

Atherosclerosis is a chronic disease of the large arteries that is responsible for the majority of cardiovascular events. In its pathogenesis, the immune system plays a pivotal role. The effectuation of the immune response through interactions between immune cells that is mediated by co-stimulatory molecules, determine atherosclerosis severity. This review will highlight the role of one of the most powerful co-stimulatory dyads, the CD154 (also known as CD40 ligand, CD40L)-CD40 dyad, in atherosclerosis. Its cell-type specific actions, signal transduction cascades and its therapeutic potentials will be discussed.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19616449     DOI： 10.1016/j.smim.2009.06.004

Source DB:  PubMed          Journal:  Semin Immunol        ISSN： 1044-5323            Impact factor:   11.130


  24 in total

1.  Blocking CD40-TRAF6 interactions by small-molecule inhibitor 6860766 ameliorates the complications of diet-induced obesity in mice.

Authors:  S M van den Berg; T T P Seijkens; P J H Kusters; B Zarzycka; L Beckers; M den Toom; M J J Gijbels; A Chatzigeorgiou; C Weber; M P J de Winther; T Chavakis; G A F Nicolaes; E Lutgens
Journal:  Int J Obes (Lond)       Date:  2014-11-13       Impact factor: 5.095

Review 2.  Update on the hyper immunoglobulin M syndromes.

Authors:  E Graham Davies; Adrian J Thrasher
Journal:  Br J Haematol       Date:  2010-02-23       Impact factor: 6.998

3.  CD40 ligand induces expression of vascular cell adhesion molecule 1 and E-selectin in orbital fibroblasts from patients with Graves' orbitopathy.

Authors:  Hao Wang; Li-Shuang Zhu; Jin-Wei Cheng; Ji-Ping Cai; You Li; Xiao-Ye Ma; Rui-Li Wei
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-01-11       Impact factor: 3.117

4.  Discrete modeling for integration and analysis of large-scale signaling networks.

Authors:  Pierre Vignet; Jean Coquet; Sébastien Auber; Matéo Boudet; Anne Siegel; Nathalie Théret
Journal:  PLoS Comput Biol       Date:  2022-06-13       Impact factor: 4.779

Review 5.  Immune checkpoint proteins: exploring their therapeutic potential to regulate atherosclerosis.

Authors:  A C Foks; J Kuiper
Journal:  Br J Pharmacol       Date:  2017-05-04       Impact factor: 8.739

6.  CD40 is essential in the upregulation of TRAF proteins and NF-kappaB-dependent proinflammatory gene expression after arterial injury.

Authors:  Zifang Song; Rong Jin; Shiyong Yu; Joshua J Rivet; Susan S Smyth; Anil Nanda; D Neil Granger; Guohong Li
Journal:  PLoS One       Date:  2011-08-18       Impact factor: 3.240

7.  Cross talk of the first-line defense TLRs with PI3K/Akt pathway, in preconditioning therapeutic approach.

Authors:  Fatemeh Pourrajab; Mohammad Baghi Yazdi; Mojtaba Babaei Zarch; Mohammadali Babaei Zarch; Seyedhossein Hekmatimoghaddam
Journal:  Mol Cell Ther       Date:  2015-05-30

8.  Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile.

Authors:  Esther Lutgens; Dirk Lievens; Linda Beckers; Erwin Wijnands; Oliver Soehnlein; Alma Zernecke; Tom Seijkens; David Engel; Jack Cleutjens; Anna M Keller; Shalin H Naik; Louis Boon; Hafid Ait Oufella; Ziad Mallat; Cory L Ahonen; Randolph J Noelle; Menno P de Winther; Mat J Daemen; Erik A Biessen; Christian Weber
Journal:  J Exp Med       Date:  2010-01-25       Impact factor: 14.307

9.  Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance.

Authors:  Antonios Chatzigeorgiou; Tom Seijkens; Barbara Zarzycka; David Engel; Marjorie Poggi; Susan van den Berg; Sjoerd van den Berg; Oliver Soehnlein; Holger Winkels; Linda Beckers; Dirk Lievens; Ann Driessen; Pascal Kusters; Erik Biessen; Ruben Garcia-Martin; Anne Klotzsche-von Ameln; Marion Gijbels; Randolph Noelle; Louis Boon; Tilman Hackeng; Klaus-Martin Schulte; Klaus Schulte; Aimin Xu; Gert Vriend; Sander Nabuurs; Kyoung-Jin Chung; Ko Willems van Dijk; Patrick C N Rensen; Norbert Gerdes; Menno de Winther; Norman L Block; Andrew V Schally; Christian Weber; Stefan R Bornstein; Gerry Nicolaes; Triantafyllos Chavakis; Esther Lutgens
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

Review 10.  Targeting co-stimulatory molecules in autoimmune disease.

Authors:  Natalie M Edner; Gianluca Carlesso; James S Rush; Lucy S K Walker
Journal:  Nat Rev Drug Discov       Date:  2020-09-16       Impact factor: 112.288
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.